Común · Saberes
Ivonescimab
Monoclonal antibody
Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer. Developed by Akeso, it has been approved in China for the treatment of epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed past tyrosine kinase inhibitor therapy, and is undergoing clinical trials elsewhere.
En Wikipedia
Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.
Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer. Developed by Akeso, it has been approved in China for the treatment of epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed past tyrosine kinase inhibitor therapy, and is undergoing clinical trials elsewhere.
Texto: Wikipedia en inglés, CC BY-SA 4.0. ·
